Authors
Carmen Rodríguez-Cerdeira, Erick Martínez-Herrera, Ditte M L Saunte, Tania Vite-Garín, Claudia Erika Fuentes-Venado, Roderick Hay, Paola Berenice Zárate-Segura, Jacek Szepietowski, Asja Prohic, Michael Arabatzis, Alexey Sergeev, Valeska Padovese, Mihael Skerlev, Rodolfo Pinto-Almazán, Mycology Task Force Group of the EADV
Published in
Journal of the European Academy of Dermatology and Venereology : JEADV. Jul 17, 2026. Epub Jul 17, 2026.
Abstract
Candida auris is a widely distributed yeast that is considered a dangerous pathogen, with reported mortality rates ranging from 30% to 60%. This yeast shows a high level of resistance to several antifungal agents commonly used to treat systemic infections. The pathogen persists on contaminated surfaces, tolerates hospital-grade disinfectants, survives desiccation and spreads easily through direct or indirect contact. It has been reported on all five continents and is increasingly prevalent in Europe.
To determine the distribution and antifungal susceptibility/resistance of Candida auris isolates identified in Europe until January 2025.
This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Searches were conducted in EBSCOhost, MEDLINE/PubMed, Scopus and SciELO databases using the terms 'Candida auris' and 'Candidozyma auris', combined with the name of each European country. It was limited to English or Spanish articles published until 31 January 2025, excluding reviews, meta-analyses and book chapters.
Ninety-one articles reporting antifungal susceptibility were retrieved, covering 2191 clinical isolates of C. auris from 16 countries. Most isolates were from Spain (n = 886, 40.44%), Italy (n = 553, 25.24%), Greece (n = 214, 9.77%), the United Kingdom (n = 182, 8.31%) and Russia (n = 108, 4.93%), accounting for 88.68% of cases. The remaining 248 isolates (11.32%) were reported across 11 other countries. Fluconazole resistance was found in 90.51% (1555/1718), while resistance to amphotericin B and echinocandins was 13.17% (223/1693) and 4.57% (76/1693), respectively.
Candida auris has been predominantly detected in Southern Europe, where the majority of clinical isolates exhibit resistance to fluconazole. Consensus is essential for timely diagnosis, targeted treatment and infection control to prevent its spread. New therapeutic options must be explored to manage Candida auris.
PMID:
42466666
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0